Angle (AGL) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Mar 2020 07:00 AM
RNS
Assessing risk of brain metastasis in lung cancer
27 Feb 2020 07:00 AM
RNS
Parsortix outperforms other CTC systems in RCC
25 Feb 2020 07:00 AM
RNS
ANGLE announce Tri-Con presentation with BioView
17 Feb 2020 07:00 AM
RNS
Data demonstrates key advantages of Parsortix
11 Feb 2020 07:00 AM
RNS
Study demonstrates Parsortix potential in melanoma
03 Feb 2020 09:10 AM
RNS
Issue of Equity
30 Jan 2020 07:00 AM
RNS
Interim Results
30 Jan 2020 07:00 AM
RNS
Change of accounting reference date
22 Jan 2020 07:00 AM
RNS
Successful face-to-face meeting with FDA
08 Jan 2020 12:33 PM
RNS
Notice of Results
23 Dec 2019 09:55 AM
RNS
Issue of Equity
07 Nov 2019 07:00 AM
RNS
Cancer centre shows Parsortix use in melanoma
30 Oct 2019 02:44 PM
RNS
Result of AGM
30 Oct 2019 07:00 AM
RNS
Q-submission to FDA containing headline data
08 Oct 2019 07:00 AM
RNS
Notice of AGM
04 Oct 2019 05:54 PM
RNS
Holding(s) in Company
04 Oct 2019 07:00 AM
RNS
European patent granted for megakaryocyte analysis
13 Sep 2019 07:00 AM
RNS
Use of Parsortix in head and neck cancer
10 Sep 2019 07:00 AM
RNS
Research with Parsortix in prostate cancer
04 Sep 2019 07:00 AM
RNS
Parsortix for Neuroendocrine Analysis in SCLC
29 Aug 2019 07:00 AM
RNS
Initiation of Ovarian Cancer Study
31 Jul 2019 07:00 AM
RNS
Prelim Results for the year ended 30 April 2019
22 Jul 2019 07:00 AM
RNS
Use of Parsortix for single cell analysis of CTCs
16 Jul 2019 09:19 AM
RNS
Holding(s) in Company
12 Jul 2019 10:22 AM
RNS
Result of General Meeting anf Total Voting Rights
28 Jun 2019 01:37 PM
RNS
Notice of Preliminary Results and Webcast
28 Jun 2019 01:08 PM
RNS
Holding(s) in Company
25 Jun 2019 05:19 PM
RNS
Result of Placing
25 Jun 2019 08:02 AM
RNS
Accelerated bookbuild to raise £18.0m
21 Jun 2019 07:00 AM
RNS
Parsortix used to investigate immunotherapy target
05 Jun 2019 07:00 AM
RNS
Completion of Ovarian Cancer Pre-Study
31 May 2019 07:00 AM
RNS
Positive Results from FDA Clinical Study
26 Apr 2019 07:00 AM
RNS
IMMUNE SUPPRESSOR CELLS PROMOTE METASTASIS
18 Apr 2019 07:00 AM
RNS
Parsortix used in new cancer assessment technique
12 Apr 2019 07:00 AM
RNS
LUNG CANCER STUDY USES ANGLE'S PARSORTIX SYSTEM
04 Apr 2019 07:00 AM
RNS
AACR 2019
11 Mar 2019 07:00 AM
RNS
Holding(s) in Company
07 Mar 2019 07:00 AM
RNS
ENROLMENT COMPLETE FOR FDA CLINICAL STUDY
28 Feb 2019 07:00 AM
RNS
FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY
25 Feb 2019 07:00 AM
RNS
CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX
11 Feb 2019 07:00 AM
RNS
Research into role of immune cells in cancer
31 Jan 2019 07:00 AM
RNS
Interim Results
29 Jan 2019 07:00 AM
RNS
NEW APPLICATION FOR PARSORTIX IN CANCER ANALYSIS
11 Jan 2019 02:05 PM
RNS
Second Price Monitoring Extn
11 Jan 2019 02:00 PM
RNS
Price Monitoring Extension
11 Jan 2019 11:05 AM
RNS
Second Price Monitoring Extn
11 Jan 2019 11:00 AM
RNS
Price Monitoring Extension
11 Jan 2019 09:05 AM
RNS
Second Price Monitoring Extn
11 Jan 2019 09:00 AM
RNS
Price Monitoring Extension
10 Jan 2019 04:41 PM
RNS
Second Price Monitoring Extn

ANGLE PLC is a commercially driven specialist medical diagnostic company with pioneering products in cancer diagnostics and foetal health. The Company's product includes Parsortix cell separation system.

Founded in 1994, Angle listed on LSE in 2004 under the ticker AGL.

UK 100

Latest directors dealings